Trial Profile
An Open-label, Multicenter Phase II Study of Afatinib Plus Weekly Taxol as Second Line Treatment for Advanced/Recurrent Gastric and Gastroesophageal Junction Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Paclitaxel
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 26 Jan 2023 Status changed from active, no longer recruiting to completed.
- 21 Apr 2021 Study design changed from randomized and parallel to open.
- 21 Apr 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.